Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

iBio (IBIO) Research & Development (2016 - 2025)

iBio (IBIO) has disclosed Research & Development for 16 consecutive years, with $4.3 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 128.02% to $4.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.0 million through Dec 2025, up 147.99% year-over-year, with the annual reading at $8.3 million for FY2025, 60.31% up from the prior year.
  • Research & Development for Q4 2025 was $4.3 million at iBio, up from $3.6 million in the prior quarter.
  • The five-year high for Research & Development was $4.3 million in Q4 2025, with the low at $904000.0 in Q1 2024.
  • Average Research & Development over 5 years is $2.3 million, with a median of $2.3 million recorded in 2021.
  • The sharpest move saw Research & Development soared 431.22% in 2021, then crashed 65.81% in 2024.
  • Over 5 years, Research & Development stood at $1.9 million in 2021, then skyrocketed by 49.49% to $2.8 million in 2022, then crashed by 44.76% to $1.5 million in 2023, then increased by 22.28% to $1.9 million in 2024, then skyrocketed by 128.02% to $4.3 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $4.3 million, $3.6 million, and $3.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.